Immunotherapy: Open Access
Open Access
ISSN: 2471-9552
ISSN: 2471-9552
Erik D’Hondt
Head of Research and Development and Regulatory, EU HQ,
Bioven Group 33 St James Square London
United Kingdom
Short Communication
Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced Non-small Cell Lung Cancer
Author(s): Erik DHondtErik DHondt
DOI:
10.4172/2471-9552.1000134